JV vs BuyoutIf the co enters into a JV, what does that mean for the prospects of a future buyout? Does it mean the buyout can only occur with the same company that entered into the JV? I assume that would be part of the terms of a JV, nobody else has a shot at buying Theralase out? Is this considered a limiting factor in such a way that a JV isn't always best for maximixing buyout/$$ potential?
I realize the company needs the funding that comes along with a JV, regardless, and possibly the expertise and sway with the FDA as well. Just trying to understand some of the limitations that a JV might introduce.